摘要
目的:探讨清肺调气汤(QFTQT)对接受免疫检查点抑制剂(immune checkpoint inhibitors,ICIs)治疗的晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)相关不良反应及肠道菌群结构的影响。方法:将59例计划接受ICIs治疗的晚期NSCLC患者(男性53例,女性6例,年龄18~75岁)随机、双盲分为两组:干预组(中药组,n=29)每个免疫治疗周期提供清肺调气汤200 mL/bid,持续7 d;对照组(非中药组,n=30)不提供中药。评价分析两组患者ICIs治疗前后的不良反应及中医临床证候评分(clinical syndrome score of traditional Chinese medicine,SLEFI)。此外,两组各随机选取10例患者收集粪便样本,并使用Illumina(San Diego,CA) MiSeq(PE2×300 bp)平台对16S rRNA的V3-V4区域进行肠道菌群测序。结果:接受清肺调气汤治疗的晚期NSCLC患者免疫检查点抑制剂相关不良反应(immune checkpoint inhibitor-related adverse events,irAEs)显著低于对照组,并与肠道菌群有关。结论:清肺调气汤可通过调节肠道菌群结构,有效调节NSCLC患者irAEs。
Objective:To explore the influence of Qingfei Tiaoqi decoction(QFTQT) on the adverse reactions and intestinal flora structure of advanced non-small cell lung cancer(NSCLC) treated with immune checkpoint inhibitors(ICIs).Methods:Fifty-nine patients with advanced NSCLC(53 males and 6 females,aged 18~75 years) who planned to receive ICIs were randomly and double-blind divided into two groups:The intervention group(Chinese medicine group,n=29) provided Qingfei Tiaoqi decoction 200 mL/bid per immunotherapy cycle for 7 days.The control group(non-Chinese medicine group,n=30) did not provide Chinese medicine.The adverse reactions and clinical syndrome score of traditional Chinese medicine(SLEFI) before and after ICIs treatment in the two groups were evaluated and analyzed.In addition,10 patients in each group were randomly selected to collect stool samples,and the intestinal flora of V3-V4 region of 16S rRNA was sequenced using Illumina(San Diego,CA) MiSeq(PE2×300 bp) platform.Results:Immune checkpoint inhibitor-related adverse events(irAEs) in patients with advanced NSCLC treated with Qingfei Tiaoqi decoction were significantly lower than those in the control group,and were related to intestinal flora.Conclusion:Qingfei Tiaoqi decoction can effectively regulate irAEs in NSCLC patients by regulating the structure of intestinal flora.
作者
王潇
陈华春
洪伟玲
杨雨顺
王胜
王超越
胡小勤
吴晓虞
WANG Xiao;CHEN Huachun;HONG Weiling;YANG Yushun;WANG Sheng;WANG Chaoyue;HU Xiaoqin;WU Xiaoyu(Jinhua Institute of Advanced Research,Zhejiang Jinhua 321000,China;College of Xingzhi,Zhejiang Normal University,Zhejiang Jinhua 321000,China;Zhejiang Jinhua Guangfu Cancer Hospital,Zhejiang Jinhua 321000,China;Nanjing University,Jiangsu Nanjing 210023,China)
出处
《现代肿瘤医学》
CAS
2024年第5期890-895,共6页
Journal of Modern Oncology
基金
浙江省基础公益研究计划(编号:LGD21C040001)
浙江省金华市中医药科学技术研究计划(编号:2022KY33)
金华高等研究院2023年教育教学研究课题(编号:B2023JY03)。
关键词
中药
免疫治疗
不良反应
肠道菌群
traditional Chinese medicine
immunotherapy
adverse reactions
intestinal flora
